Printer Friendly

LAWSUITS FILED AGAINST MEDIMMUNE

 GAITHERSBURG, Md., Dec. 10 /PRNewswire/ -- MedImmune, Inc. (NASDAQ: MEDI) today confirmed, as announced on wire services on Tuesday, Dec. 7, that lawsuits have been filed against the Company and certain of its officers and directors following the stock price drop during and after the Dec. 2, 1993 meeting of the Blood Products Advisory Committee of the United States Food and Drug Administration (FDA). The suits seek unspecified money damages, purportedly on behalf of a class of the Company's shareholders, and allege that the defendants issued misleading statements, in violation of the federal securities laws, relating to the status of the review by the FDA of the Company's RespiGam(TM) product.
 The Company believes that the allegations are without merit and intends to vigorously defend these lawsuits.
 MedImmune, Inc. was formed in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of certain infectious diseases and cancers. MedImmune's corporate headquarters are in Gaithersburg.
 -0- 12/10/93
 /CONTACT: David M. Mott, vice president - business development and planning of MedImmune, 301-417-0770, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-696-4455/
 (MEDI)


CO: MedImmune, Inc. ST: Maryland IN: MTC SU:

LG -- NY061 -- 2698 12/10/93 14:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 10, 1993
Words:203
Previous Article:GREEN POINT DEPOSITORS APPROVE CONVERSION
Next Article:FMC GOLD ANNOUNCES ASSET WRITE-DOWN, OTHER CHARGES
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters